Enzymatic DNA synthesis is a well-established technique of DNA synthesis, which is useful in synthetic biology, genetic engineering, therapeutic antibody production, vaccine designing, and other advanced biological procedures. It has also proven helpful in maintaining DNA libraries and synthesizing custom DNA molecules.
Down syndrome, autism spectrum disorder, cancer, diabetes, cystic fibrosis, and sickle cell anemia are a few of the commonly known genetic disorders. Per the Global Genes, more than 10,000 different genetic and rare diseases have been identified, and ~400 million people suffer from rare diseases. Some genetic disorders cause symptoms at birth, while others develop over time. The global burden of genetic diseases appears to be increasing. According to the National Center for Biotechnology Information (NCBI), a US-based medical organization, as of November 2021, genetic disorders were identified in 9.4% of pediatric patients, with 44.7% being critically ill newborns. In addition, 13.17 million patients in the US suffer from unique genetic disorders. According to the Centers for Disease Control and Prevention (CDC) 2022 report, sickle cell disease affects ~100,000 Americans, and it occurs in 1 in 356 African American births. Cystic fibrosis, another common genetic disease worldwide, affects ~30,000 people in the US, and ~1,000 new cases are treated annually. Enzymatic DNA synthesis is a well-established DNA synthesis technique useful in synthetic biology, genetic engineering, and therapeutic antibody studies. In conjunction with enzymatic assays, DNA synthesis shows greater diagnostic possibilities. This method provides important information about people at risk and helps them make important decisions regarding disease diagnosis and medication. Hence, with the rising prevalence of genetic disorders across the world, people are becoming more aware of the need for the early detection of these genetic flaws, which propels the growth of the enzymatic DNA synthesis market
Enzymatic DNA synthesis techniques are not mature enough, and further optimization is required before they are rolled out for widespread use. Most are based on the naturally occurring enzyme terminal deoxynucleotidyl transferase (TdT), which is used in biological systems to add new bases to a DNA sequence. TdT-based method is an improved one over the chemical procedure as it avoids the production of hazardous waste. However, the high costs and low accuracy of this enzyme hinder its use in in vitro DNA synthesis. The TdT enzyme is too permissive, adding wrong bases more often than it should. As a result, TdT-based oligos have more sequence errors and may require the same or even more post-synthesis quality control steps, increasing the time and cost of the synthesis process. While working with this enzyme, scientists need to add more reagents to build their target sequence, which further adds to the cost of the entire synthesis process. The cost per base of synthetic DNA obtained using TdT is much high than conventionally synthesized genetic materials. Thus, high costs and complex procedures limit the growth of the enzymatic DNA synthesis market.
Based on product type, the enzymatic DNA synthesis market is segmented into custom DNA synthesis and DNA library synthesis. The DNA library synthesis segment held the largest market share in 2021. Further, the custom DNA synthesis segment is anticipated to register the highest CAGR during the forecast period (2022–2028).
Based on application, the enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and other applications. The synthetic biology segment held the largest share of the market in 2021. The enzymatic DNA synthesis market for therapeutic antibodies application is expected to grow at the highest CAGR during the forecast period.
Based on end user, the enzymatic DNA synthesis market is segmented into academic & research institutes, biotechnology & pharmaceutical companies, diagnostic laboratories, and others. The biotechnology & pharmaceutical companies segment held the largest share of the market in 2021. The academic & research institutes segment is anticipated to register the highest CAGR in the market during the forecast period (2022–2028).
The regional trends and factors influencing the Enzymatic DNA Synthesis Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Enzymatic DNA Synthesis Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 240.96 Million |
| Market Size by 2028 | US$ 2,244.88 Million |
| Global CAGR (2022 - 2028) | 45.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Enzymatic DNA Synthesis Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Enzymatic DNA Synthesis Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
Based on technology, the enzymatic DNA synthesis market is segmented into SOLA, CRISPR, PCR, and others. The PCR segment has the largest share in 2021 and is expected to continue a similar trend during the forecast period. On the other hand, the CRISPR segment is expected to witness the highest CAGR during the forecast period.
Strategies that are prominently adopted by companies in the enzymatic DNA synthesis market mergers and acquisitions. A few recent developments by key market players are listed below:
Enzymatic DNA synthesis (EDS) offers significant advantages in terms of accessibility and convenience, changing the pace and control of iteration and innovation with less environmental impact. The enzymes involved in DNA replication act coordinated to synthesize both leading and lagging strands of DNA simultaneously at the replication fork. Purported benefits of enzymatic synthesis include the ability to avoid the use of harsh chemical substances (which often result in toxic waste) and an ever-increasing ability to produce longer and longer strands of DNA, which in turn not only leads to a "more green" form of DNA synthesis, but also some incredibly powerful new uses for the longer DNA chains (e.g., vaccines, therapeutics, and data storage).
The factors that are driving the growth of the enzymatic DNA synthesis market are the rising prevalence of genetic disorders and surging number of product launches. Also, the growing demand for enzymatic DNA synthesis procedures is expected to provide opportunity for the enzymatic DNA synthesis market in forecasted period.
The enzymatic DNA synthesis market majorly consists of the players, such as Telesis Bio Inc, Evonetix, Ansa Biotechnologies, Inc., Camena Bio, GenScript Biotech Corp., Molecular Assemblie, DNA Script, Touchlight, Synbio Technologies, and Twist Bioscience.
The enzymatic DNA synthesis market is estimated to be valued at US$ 240.96 million in 2022.
The CAGR value of the enzymatic DNA synthesis market during the forecasted period of 2022-2028 is 45.1%.
The Asia Pacific region is expected to be the fastest-growing region in the enzymatic DNA synthesis market over the forecast period due to increasing government investment to provide healthcare facilities, growing advancements in healthcare infrastructure, greater adoption of advanced technologies, and rising healthcare spending in countries such as China, Japan, and India.
The enzymatic DNA synthesis market is expected to be valued at US$ 2,244.88 million in 2028.
The DNA library synthesis segment held the largest share of the market in 2022, owing to the various advantages offered by DNA library synthesis such as systematic, unbiased investigations such as high-throughput screening for discovery biology, directed evolution for protein engineering, and in vitro molecular optimization to generate mutant proteins with improved or novel properties. However, the custom DNA synthesis segment is estimated to register the highest CAGR in the market during the forecast period.